VCYT Q2 2019 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+32.5% YoY

Gross Profit

$21M70.9% margin

Operating Income

-$3M-10.3% margin

Net Income

-$2M-8.3% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+2.1%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$3M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$252M

Total Liabilities

$28M

Stockholders' Equity

$224M

Cash & Equivalents

$193M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$23M	+32.5%
Gross Profit	$21M	$15M	+47.3%
Operating Income	-$3M	-$6M	+47.6%
Net Income	-$2M	-$6M	+60.1%

Revenue Segments

Provision of Data and Fulfillment of Milestones

$3M68%

Provision of Data

$1M25%

Service

$250,0005%

Product

$90,0002%